Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Cancers (ECHO-202/KEYNOTE-037)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT02178722
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:38:47.869036+00:00
Published At
2019-12-19T00:00:00+00:00
Record Updated At
2022-02-14
Results Posted At
2019-12-19
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Microsatellite-instability (MSI) High Colorectal Cancer (CRC)", "Endometrial Cancer", "Head and Neck Cancer", "Hepatocellular Carcinoma (HCC)", "Gastric Cancer", "Lung Cancer", "Lymphoma", "Renal Cell Carcinoma (RCC)", "Ovarian Cancer", "Solid Tumors", "UC (Urothelial Cancer)", "Melanoma", "Bladder Cancer", "Triple Negative Breast Cancer (TNBC)"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2022-02-14"
protocolSection.identificationModule.nctId
"NCT02178722"
protocolSection.identificationModule.officialTitle
"A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Cancers (ECHO-202/KEYNOTE-037)"
protocolSection.statusModule.overallStatus
"COMPLETED"
protocolSection.designModule.phases
["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
"2019-12-19"

Study condition terms

  • Microsatellite-instability (MSI) High Colorectal Cancer (CRC) (protocolSection.conditionsModule.conditions)
  • Endometrial Cancer (protocolSection.conditionsModule.conditions)
  • Head and Neck Cancer (protocolSection.conditionsModule.conditions)
  • Hepatocellular Carcinoma (HCC) (protocolSection.conditionsModule.conditions)
  • Gastric Cancer (protocolSection.conditionsModule.conditions)
  • Lung Cancer (protocolSection.conditionsModule.conditions)
  • Lymphoma (protocolSection.conditionsModule.conditions)
  • Renal Cell Carcinoma (RCC) (protocolSection.conditionsModule.conditions)
  • Ovarian Cancer (protocolSection.conditionsModule.conditions)
  • Solid Tumors (protocolSection.conditionsModule.conditions)
  • UC (Urothelial Cancer) (protocolSection.conditionsModule.conditions)
  • Melanoma (protocolSection.conditionsModule.conditions)
  • Bladder Cancer (protocolSection.conditionsModule.conditions)
  • Triple Negative Breast Cancer (TNBC) (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.